Hedy Kindler to Humans
This is a "connection" page, showing publications Hedy Kindler has written about Humans.
Connection Strength
1.762
-
Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. Cancer. 2023 05 01; 129(9):1411-1418.
Score: 0.030
-
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Clin Oncol. 2022 12 01; 40(34):3929-3939.
Score: 0.029
-
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol. 2022 04; 23(4):540-552.
Score: 0.028
-
Systemic Therapy for Mesothelioma: Turning the Corner. JCO Oncol Pract. 2022 06; 18(6):e843-e845.
Score: 0.028
-
Understanding the new therapeutic options for mesothelioma. Lancet Oncol. 2021 10; 22(10):1353-1355.
Score: 0.027
-
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
Score: 0.026
-
5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Response. Clin Cancer Res. 2020 07 15; 26(14):3890.
Score: 0.025
-
Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. Clin Lung Cancer. 2020 11; 21(6):553-561.e1.
Score: 0.025
-
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol. 2019 12 01; 30(12):1959-1968.
Score: 0.024
-
Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply. N Engl J Med. 2019 10 10; 381(15):1492-1493.
Score: 0.024
-
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 07 25; 381(4):317-327.
Score: 0.023
-
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636.
Score: 0.023
-
A Glimmer of Hope for Pancreatic Cancer. N Engl J Med. 2018 12 20; 379(25):2463-2464.
Score: 0.022
-
Reply to D. de Fonseka et al. J Clin Oncol. 2018 09 10; 36(26):2746-2747.
Score: 0.022
-
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2018 04; 14(4):256-264.
Score: 0.021
-
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 05 01; 36(13):1343-1373.
Score: 0.021
-
Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362.
Score: 0.021
-
The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma. J Oncol Pract. 2016 10; 12(10):936-937.
Score: 0.019
-
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.
Score: 0.018
-
Current controversies in the stage-specific multidisciplinary management of pancreatic cancer. Am Soc Clin Oncol Educ Book. 2014; e157-64.
Score: 0.016
-
MARS: a sense of perspective and an inconvenient truth. J Thorac Oncol. 2013 May; 8(5):e49-50.
Score: 0.015
-
Peritoneal mesothelioma: the site of origin matters. Am Soc Clin Oncol Educ Book. 2013; 182-8.
Score: 0.015
-
Robust data: the essential foundation of a revised staging system for pleural mesothelioma. J Thorac Oncol. 2012 Nov; 7(11):1623-4.
Score: 0.015
-
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80.
Score: 0.014
-
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012 Sep; 77(3):567-71.
Score: 0.014
-
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012 Nov; 23(11):2834-2842.
Score: 0.014
-
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15.
Score: 0.014
-
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012 Jun; 76(3):393-6.
Score: 0.014
-
Surgery for mesothelioma? The debate continues. Lancet Oncol. 2011 Aug; 12(8):713-4.
Score: 0.013
-
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Jun; 30(3):1211-5.
Score: 0.013
-
Update on malignant pleural mesothelioma. Semin Respir Crit Care Med. 2011 Feb; 32(1):102-10.
Score: 0.013
-
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011 Mar; 12(3):256-62.
Score: 0.013
-
Computerized segmentation and measurement of malignant pleural mesothelioma. Med Phys. 2011 Jan; 38(1):238-44.
Score: 0.013
-
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Clin Colorectal Cancer. 2010 Dec; 9(5):290-6.
Score: 0.013
-
[Screening for risk of child abuse and neglect. A practicable method?]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Oct; 53(10):1073-9.
Score: 0.013
-
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Feb; 30(1):382-6.
Score: 0.013
-
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 01; 28(22):3617-22.
Score: 0.012
-
Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009 Sep; 136(3):888-896.
Score: 0.012
-
The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2010 Dec; 28(6):854-8.
Score: 0.012
-
Malignant pleural mesothelioma. J Clin Oncol. 2009 Apr 20; 27(12):2081-90.
Score: 0.011
-
Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. Am J Clin Oncol. 2008 Dec; 31(6):553-6.
Score: 0.011
-
Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol. 2008 Jun; 9(2-3):171-9.
Score: 0.011
-
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest New Drugs. 2009 Feb; 27(1):75-81.
Score: 0.011
-
Current state and future directions of pleural mesothelioma imaging. Lung Cancer. 2008 Mar; 59(3):411-20.
Score: 0.010
-
Pancreatic cancer: an update. Curr Oncol Rep. 2007 May; 9(3):170-6.
Score: 0.010
-
Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer. 2006 May; 52(2):141-8.
Score: 0.009
-
Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin North Am. 2005 Dec; 19(6):1137-45, viii.
Score: 0.009
-
Front-line therapy of advanced pancreatic cancer. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S33-6.
Score: 0.009
-
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
Score: 0.009
-
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs. 2005 Oct; 23(5):489-93.
Score: 0.009
-
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005 Oct; 16(10):1639-45.
Score: 0.009
-
Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. Am J Clin Oncol. 2005 Aug; 28(4):340-4.
Score: 0.009
-
A vascular ring without compression: double aortic arch presenting as a coincidental finding during cardiac catheterisation. Heart. 2005 Jun; 91(6):773.
Score: 0.009
-
Chemotherapy for advanced pancreatic cancer: past, present, and future. Curr Oncol Rep. 2005 May; 7(3):186-95.
Score: 0.009
-
In focus: advanced pancreatic cancer. Clin Adv Hematol Oncol. 2005 May; 3(5):420-2.
Score: 0.009
-
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2005 Jun; 48(3):423-8.
Score: 0.009
-
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol. 2004 Dec; 27(6):565-9.
Score: 0.008
-
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Invest New Drugs. 2004 Aug; 22(3):323-7.
Score: 0.008
-
Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer. 2004 Aug; 45 Suppl 1:S125-7.
Score: 0.008
-
The emerging role of pemetrexed for the treatment of malignant mesothelioma. Oncology (Williston Park). 2004 Jul; 18(8 Suppl 5):49-53.
Score: 0.008
-
Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk. Ann Surg Oncol. 2024 May; 31(5):3339-3349.
Score: 0.008
-
Mesothelioma in situ of the peritoneum: report of three cases and review of the literature. Histopathology. 2024 Feb; 84(3):492-506.
Score: 0.008
-
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023 Nov; 29(11):2814-2824.
Score: 0.008
-
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2023 11 01; 30(11).
Score: 0.008
-
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology. Am J Clin Pathol. 2023 09 01; 160(3):238-246.
Score: 0.008
-
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma. J Thorac Oncol. 2023 12; 18(12):1689-1702.
Score: 0.008
-
Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma. JAMA Netw Open. 2023 08 01; 6(8):e2327351.
Score: 0.008
-
Management of Patients With Pancreatic Cancer Using the "Right Track" Model. Oncologist. 2023 07 05; 28(7):584-595.
Score: 0.008
-
Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation. Cancer. 2023 07 15; 129(14):2152-2160.
Score: 0.008
-
Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma. JCO Precis Oncol. 2023 01; 7:e2200196.
Score: 0.007
-
Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec; 29(6 Suppl 18):49-53.
Score: 0.007
-
A population-based evaluation of tunica vaginalis mesothelioma: An analysis of the National Cancer Database. Urol Oncol. 2023 01; 41(1):52.e11-52.e20.
Score: 0.007
-
The pemetrexed/gemcitabine combination in pancreatic cancer. Cancer. 2002 Aug 15; 95(4 Suppl):928-32.
Score: 0.007
-
Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). Oncologist. 2022 06 08; 27(6):e494-e505.
Score: 0.007
-
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6).
Score: 0.007
-
Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. J Thorac Oncol. 2022 07; 17(7):873-889.
Score: 0.007
-
Pemetrexed in patients with gastrointestinal carcinoma. Semin Oncol. 2002 Apr; 29(2 Suppl 5):42-9.
Score: 0.007
-
The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. Abdom Radiol (NY). 2022 05; 47(5):1725-1740.
Score: 0.007
-
Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. JAMA Netw Open. 2022 02 01; 5(2):e220145.
Score: 0.007
-
The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol. 2002 Feb; 29(1):70-6.
Score: 0.007
-
Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). J Clin Oncol. 2022 03 01; 40(7):740-751.
Score: 0.007
-
Metastatic colorectal cancer. Curr Treat Options Oncol. 2001 Dec; 2(6):459-71.
Score: 0.007
-
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021 11; 27(11):1910-1920.
Score: 0.007
-
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 02; 126(2):265-274.
Score: 0.007
-
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. Int J Cancer. 2022 01 15; 150(2):279-289.
Score: 0.007
-
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
Score: 0.007
-
Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance). Angiogenesis. 2022 02; 25(1):47-55.
Score: 0.007
-
Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). JNCI Cancer Spectr. 2021 06; 5(3).
Score: 0.007
-
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med. 2021 06; 9(6):613-621.
Score: 0.007
-
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021 02; 9(2).
Score: 0.006
-
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2001 Feb-Mar; 31(2-3):311-7.
Score: 0.006
-
Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br J Cancer. 2021 02; 124(3):564-566.
Score: 0.006
-
Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. Mod Pathol. 2021 02; 34(2):380-395.
Score: 0.006
-
Malignant pleural mesothelioma. Curr Treat Options Oncol. 2000 Oct; 1(4):313-26.
Score: 0.006
-
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 10; 21(10):1353-1365.
Score: 0.006
-
Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul; 9(7):1635-49.
Score: 0.006
-
The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). Cancer Epidemiol Biomarkers Prev. 2020 08; 29(8):1692-1695.
Score: 0.006
-
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. J Clin Oncol. 2020 06 01; 38(16):1824-1835.
Score: 0.006
-
Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. J Clin Oncol. 2020 05 01; 38(13):1442-1454.
Score: 0.006
-
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
Score: 0.006
-
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol. 2020 05 01; 38(13):1378-1388.
Score: 0.006
-
Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer. 1999 Nov 15; 86(10):1985-91.
Score: 0.006
-
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24.
Score: 0.006
-
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. J Thorac Oncol. 2020 01; 15(1):29-49.
Score: 0.006
-
Internet-based physician's workbench as user interface for a central medical case repository. Methods Inf Med. 1999 Sep; 38(3):194-9.
Score: 0.006
-
Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731.
Score: 0.006
-
Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec; 26(13):4489-4497.
Score: 0.006
-
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Pharmacogenet Genomics. 2019 08; 29(6):123-131.
Score: 0.006
-
Reply to K. Masuda et al. J Clin Oncol. 2019 09 01; 37(25):2294-2295.
Score: 0.006
-
Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2019 10 01; 25(19):5787-5798.
Score: 0.006
-
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019 Sep 15; 25(18):5493-5502.
Score: 0.006
-
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. Invest New Drugs. 2020 04; 38(2):457-467.
Score: 0.006
-
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A. 2019 04 30; 116(18):9008-9013.
Score: 0.006
-
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. J Clin Oncol. 2019 04 01; 37(10):790-798.
Score: 0.006
-
Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). J Natl Cancer Inst. 2019 02 01; 111(2):170-179.
Score: 0.006
-
Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma. Eur Radiol. 2019 Jun; 29(6):2981-2988.
Score: 0.006
-
Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep. 2018 11 05; 8(1):16332.
Score: 0.006
-
Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018 12; 8(12):1548-1565.
Score: 0.006
-
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. Am J Clin Oncol. 1998 Oct; 21(5):438-41.
Score: 0.006
-
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 11; 13(11):1655-1667.
Score: 0.006
-
Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors. Mol Cancer Res. 2019 01; 17(1):70-83.
Score: 0.005
-
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. J Clin Oncol. 2018 10 01; 36(28):2863-2871.
Score: 0.005
-
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272.
Score: 0.005
-
Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One. 2018; 13(7):e0199244.
Score: 0.005
-
Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. Eur Radiol. 2019 Feb; 29(2):682-688.
Score: 0.005
-
Providing dermatological photographs using the multimedia extension of the international computer database for radiation accident case histories. Int J Med Inform. 1998 Jul; 51(1):39-50.
Score: 0.005
-
Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial. JAMA Oncol. 2018 06 01; 4(6):783-790.
Score: 0.005
-
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma. World J Surg. 2018 04; 42(4):1036-1045.
Score: 0.005
-
The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer. J Geriatr Oncol. 2018 07; 9(4):367-372.
Score: 0.005
-
A pragmatic implementation of medical temporal reasoning for clinical medicine. Comput Biol Med. 1998 Mar; 28(2):105-20.
Score: 0.005
-
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2018 04 10; 36(11):1112-1120.
Score: 0.005
-
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018 04 03; 19(4):316-327.
Score: 0.005
-
Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev. 2018 04; 27(4):438-445.
Score: 0.005
-
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer. 2018 04 01; 124(7):1374-1382.
Score: 0.005
-
A multimedia database for dermatology. Stud Health Technol Inform. 1998; 52 Pt 1:70-4.
Score: 0.005
-
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer. 2018 01; 89:19-26.
Score: 0.005
-
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48.
Score: 0.005
-
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017 09; 18(9):1261-1273.
Score: 0.005
-
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). Ann Oncol. 2017 Jun 01; 28(6):1359-1367.
Score: 0.005
-
A phase II study of a human anti-PDGFRa monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Ann Oncol. 2017 03 01; 28(3):541-546.
Score: 0.005
-
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist. 2017 02; 22(2):189-198.
Score: 0.005
-
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Br J Cancer. 2017 Mar 14; 116(6):697-702.
Score: 0.005
-
Internet access to a medical case repository for teaching and analysis. Proc AMIA Annu Fall Symp. 1997; 543-7.
Score: 0.005
-
Save medical personnel's time by improved user interfaces. Stud Health Technol Inform. 1997; 45:61-5.
Score: 0.005
-
Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma. Ann Thorac Surg. 2017 Mar; 103(3):962-966.
Score: 0.005
-
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2112-2119.
Score: 0.005
-
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2089-2099.
Score: 0.005
-
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2100-2111.
Score: 0.005
-
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Sci Rep. 2016 09 13; 6:32992.
Score: 0.005
-
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma. Ann Thorac Surg. 2016 Oct; 102(4):1059-66.
Score: 0.005
-
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 08 17; 151(8):e161137.
Score: 0.005
-
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Sci Rep. 2016 Apr 15; 6:24578.
Score: 0.005
-
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar; 45(3):370-5.
Score: 0.005
-
Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016 Jun; 49(6):1642-7.
Score: 0.005
-
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 06 15; 22(12):2874-84.
Score: 0.005
-
Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly. Ann Thorac Surg. 2015 Nov; 100(5):1868-74.
Score: 0.004
-
Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2015 Nov 01; 33(31):3598-607.
Score: 0.004
-
Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma. Ann Thorac Surg. 2015 May; 99(5):1775-80.
Score: 0.004
-
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015 Apr; 16(4):447-56.
Score: 0.004
-
Radiologic-pathologic correlation of mesothelioma tumor volume. Lung Cancer. 2015 Mar; 87(3):278-82.
Score: 0.004
-
Necessity of extensive comprehensive databases for the improvement and test of diagnostic guidelines. Medinfo. 1995; 8 Pt 2:1055-8.
Score: 0.004
-
A general hypertext-based explanation component for medical knowledge-based systems. Medinfo. 1995; 8 Pt 2:969-73.
Score: 0.004
-
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol. 2015 May 10; 33(14):1551-6.
Score: 0.004
-
Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 2015 Jan; 107(1):336.
Score: 0.004
-
Haemopoietic cell renewal in radiation fields. Adv Space Res. 1994 Oct; 14(10):541-54.
Score: 0.004
-
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 01; 20(23):5927-36.
Score: 0.004
-
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 2014; 9(9):e105919.
Score: 0.004
-
Tumor genome analysis includes germline genome: are we ready for surprises? Int J Cancer. 2015 Apr 01; 136(7):1559-67.
Score: 0.004
-
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). J Natl Cancer Inst. 2014 Aug; 106(8).
Score: 0.004
-
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer. 2014 Sep; 85(3):429-34.
Score: 0.004
-
Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). PLoS One. 2014; 9(6):e99816.
Score: 0.004
-
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Target Oncol. 2015 Mar; 10(1):65-76.
Score: 0.004
-
The Vulnerable Elders Survey-13 predicts mortality in older adults with later-stage colorectal cancer receiving chemotherapy: a prospective pilot study. J Am Geriatr Soc. 2013 Nov; 61(11):2043-4.
Score: 0.004
-
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res. 2013 Dec 15; 19(24):6957-66.
Score: 0.004
-
Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer. 2013 Dec; 12(4):233-8.
Score: 0.004
-
Variability of tumor area measurements for response assessment in malignant pleural mesothelioma. Med Phys. 2013 Aug; 40(8):081916.
Score: 0.004
-
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin Cancer Res. 2013 Aug 01; 19(15):4282-9.
Score: 0.004
-
Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma. J Thorac Oncol. 2013 Apr; 8(4):478-86.
Score: 0.004
-
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013 Aug; 20(8):2787-95.
Score: 0.004
-
Disease volumes as a marker for patient response in malignant pleural mesothelioma. Ann Oncol. 2013 Apr; 24(4):999-1005.
Score: 0.004
-
Optimization of response classification criteria for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012 Nov; 7(11):1728-34.
Score: 0.004
-
Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. PLoS One. 2012; 7(9):e45330.
Score: 0.004
-
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg. 2012 Oct; 94(4):1086-92.
Score: 0.004
-
Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer. Qual Life Res. 2013 Jun; 22(5):1105-12.
Score: 0.004
-
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol. 2012 Apr; 7(4):755-9.
Score: 0.004
-
Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. Int Surg. 2012 Jan-Mar; 97(1):65-70.
Score: 0.003
-
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan 15; 18(2):577-84.
Score: 0.003
-
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage. 2012 Feb; 43(2):205-17.
Score: 0.003
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.003
-
Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer. 2012 Jan 15; 118(2):571-8.
Score: 0.003
-
Personalized colon cancer care in 2010. Semin Oncol. 2011 Apr; 38(2):284-308.
Score: 0.003
-
Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication. Acad Radiol. 2011 Mar; 18(3):294-8.
Score: 0.003
-
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010; 15(12):1310-9.
Score: 0.003
-
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct; 5(10):1655-61.
Score: 0.003
-
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs. 2011 Dec; 29(6):1475-81.
Score: 0.003
-
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12.
Score: 0.003
-
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009 Jun 20; 27(18):3007-13.
Score: 0.003
-
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34.
Score: 0.003
-
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009 Sep; 64(4):777-83.
Score: 0.003
-
Protein kinase C beta in malignant pleural mesothelioma. Anticancer Drugs. 2008 Oct; 19(9):841-8.
Score: 0.003
-
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15; 113(4):808-14.
Score: 0.003
-
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 Aug; 44(12):1684-92.
Score: 0.003
-
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008 Jul 20; 26(21):3567-72.
Score: 0.003
-
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. J Thorac Oncol. 2008 Apr; 3(4):417-21.
Score: 0.003
-
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol. 2008 Mar 20; 26(9):1465-71.
Score: 0.003
-
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol. 2008 Jan; 15(1):158-64.
Score: 0.003
-
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Apr 01; 70(5):1431-7.
Score: 0.003
-
Extensive aortic dissection presenting as acute inferior myocardial infarction. Heart. 2007 Oct; 93(10):1225.
Score: 0.003
-
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007 Oct 10; 25(29):4557-61.
Score: 0.003
-
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007 Sep 01; 13(17):5144-9.
Score: 0.003
-
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007 Jul 20; 25(21):3055-60.
Score: 0.003
-
A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. J Gastrointest Surg. 2007 Jun; 11(6):758-66.
Score: 0.003
-
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):549-58.
Score: 0.003
-
The cancer and leukemia group B respiratory committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3581s-8s.
Score: 0.002
-
Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol. 2006 Nov; 17(11):1615-9.
Score: 0.002
-
Variability in mesothelioma tumor response classification. AJR Am J Roentgenol. 2006 Apr; 186(4):1000-6.
Score: 0.002
-
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 01; 66(1):352-61.
Score: 0.002
-
Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol. 2006 Jan; 154(1):191-2.
Score: 0.002
-
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. Acad Radiol. 2005 Oct; 12(10):1301-9.
Score: 0.002
-
Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart. 2006 Mar; 92(3):357-60.
Score: 0.002
-
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol. 2005 Oct; 56(4):421-6.
Score: 0.002
-
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005 Mar 15; 11(6):2300-4.
Score: 0.002
-
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs. 2005 Jan; 23(1):31-7.
Score: 0.002
-
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11.
Score: 0.002
-
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res. 2004 Nov 01; 10(21):7244-51.
Score: 0.002
-
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6111-8.
Score: 0.002
-
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8.
Score: 0.002
-
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 01; 10(13):4363-8.
Score: 0.002
-
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004 Jul 01; 10(13):4406-11.
Score: 0.002
-
A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol. 2004 Jun; 15(6):928-32.
Score: 0.002
-
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer. 2004 May; 44(2):251-9.
Score: 0.002
-
Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys. 2004 May; 31(5):1105-15.
Score: 0.002
-
Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol. 2003 Aug; 14(8):1270-3.
Score: 0.002
-
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003 May 15; 97(10):2480-6.
Score: 0.002
-
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003 Apr 15; 21(8):1556-61.
Score: 0.002
-
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res. 2002 Apr; 8(4):1042-8.
Score: 0.002
-
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol. 2002 Feb; 29(1):82-96.
Score: 0.002
-
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7.
Score: 0.002
-
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. Lung Cancer. 2001 Nov; 34(2):289-95.
Score: 0.002
-
Oral fluoropyrimidine treatment of colorectal cancer. Clin Colorectal Cancer. 2001 Aug; 1(2):95-103.
Score: 0.002
-
Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann Oncol. 2000 Sep; 11(9):1161-4.
Score: 0.002
-
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999 Jan 21; 340(3):190-5.
Score: 0.001
-
The clinical development of paclitaxel and the paclitaxel/carboplatin combination. Eur J Cancer. 1998 Sep; 34(10):1543-8.
Score: 0.001
-
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 1997 Dec; 8(12):1269-71.
Score: 0.001
-
Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-138-S12-143.
Score: 0.001
-
Criteria for the selection of radiation accident victims for stem cell transplantation. Stem Cells. 1997; 15 Suppl 2:287-97.
Score: 0.001
-
[AUTORADIOGRAPHIC STUDIES OF SKIN TRANSPLANTATION]. Langenbecks Arch Klin Chir Ver Dtsch Z Chir. 1964 Nov 17; 308:1001-3.
Score: 0.001
-
[Paper electrophoresis in knee joint effusions]. Dtsch Med Wochenschr. 1959 Dec 04; 84:2192-5.
Score: 0.000
-
[Treatment of severe forms of hematogenous osteomyelitis with special reference to protein metabolism]. Bruns Beitr Klin Chir. 1958 Jun; 196(4):464-75.
Score: 0.000
-
[Topical diagnosis of pheochromocytoma]. Fortschr Geb Rontgenstr Nuklearmed. 1956 Sep; 85(3):330-3.
Score: 0.000
-
[Treatment of the pleural empyema]. Dtsch Med Wochenschr. 1956 Jun 22; 81(25):1009-11.
Score: 0.000
-
[Surgical treatment of juvenile bone cysts and giant cell tumors]. Chirurg. 1955 Jan; 26(1):17-20.
Score: 0.000
-
[Specific tonicity of the muscles of the sole of the foot and the lower leg and its relation to foot deformities]. Z Orthop Ihre Grenzgeb. 1952; 81(4):607-13.
Score: 0.000
-
[Operative treatment of recurrent patellar dislocation]. Zentralbl Chir. 1951; 76(14):989-92.
Score: 0.000
-
[Effect of anemia upon the specific tonus of the voluntarily relaxed muscles]. Z Kreislaufforsch. 1950 May; 39(9-10):289-95.
Score: 0.000
-
[Arrangement of experiment for extracorporeal perfusion of pig's liver]. Med Welt. 1969 Jan 11; 2:82-5.
Score: 0.000
-
[Treatment of hepatic coma by means of liver perfusion]. Langenbecks Arch Chir. 1969; 325:1123-8.
Score: 0.000